Onartuzumab
Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].
Product Specifications
CAS Number
1133766-06-9
Product Name Alternative
MetMAb
UNSPSC
12352203
Target
C-Met/HGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/onartuzumab.html
Purity
99.62
Solubility
10 mM in DMSO
Smiles
[Onartuzumab]
Molecular Weight
(98.907 kDa)
References & Citations
[1]Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110 (32) :E2987-96.|[2]Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165 (1) :186-197.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740992-500 1x 500 µL
SOX10 (SOX10/992), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC882241-500 1x 500 µL
Glutathione S-Transferase Mu1 (GSTM1) (CPTC-GSTMu1-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 